NCT06647524 Pilot fMRI Studies of Aging-Related Effects of THC
| NCT ID | NCT06647524 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Yale University |
| Condition | THC |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 10 participants in total. It began in 2025-07-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to begin investigating acute impairment of various forms of memory and learning by Tetrahydrocannabinol (THC) in cannabis (CNB) compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults.
Eligibility Criteria
Inclusion Criteria: * CNB use within past 2 years and felt "high" when used. * Able to read, speak, and understand English. * Able and willing to provide written informed consent, and willing to commit to the study protocol. Exclusion Criteria: * Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence. * Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment * History of adverse effects with CNB * CNB users who are abstaining * IQ \<80 on the Wechsler Abbreviated Scale of Intelligence * Inability to comprehend written instructions using the WRAT 4 reading achievement test * Pregnant, breastfeeding, and ineffective birth control methods * Unable or unsafe to have an MRI * Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy * History of head trauma with loss of consciousness \> 30 minutes or concussion lasting 30 days * Focal brain lesion seen on structural MRI * Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome) * Anyone deemed unsafe to study personnel for any reason * Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study * Significant pain and/or reduced mobility in the arms
Contact & Investigator
Godfrey Pearlson, M.D
PRINCIPAL INVESTIGATOR
Founding Director, Olin Neuropsychiatry Center; Yale University
Frequently Asked Questions
Who can join the NCT06647524 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying THC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06647524 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06647524 currently recruiting?
Yes, NCT06647524 is actively recruiting participants. Contact the research team at godfrey.pearlson@yale.edu for enrollment information.
Where is the NCT06647524 trial being conducted?
This trial is being conducted at Hartford, United States.
Who is sponsoring the NCT06647524 clinical trial?
NCT06647524 is sponsored by Yale University. The principal investigator is Godfrey Pearlson, M.D at Founding Director, Olin Neuropsychiatry Center; Yale University. The trial plans to enroll 10 participants.